Progress on monoclonal antibodies in the treatment of multidrug-resistant bacterial infections
During the Corona Virus Disease 2019 pandemic,the World Health Organization issued guidelines suggesting that antibiotics should not be used in patients with suspected or confirmed mild novel coronavirus infection unless there is clinical suspicion of bacterial infection.However,recent statistical studies have pointed out that the proportion of non-essential antibiotics used by patients infected with the novel coronavirus is very high,resulting in a large number of bacteria resistances,causing tens of thousands of lives and huge economic losses.The role of antibiotics in the treatment of diseases caused by drug-resistant bacteria is increasingly limited,and it has become an urgent social issue in the post-epidemic era.In recent years,with the progress of biotechnology and the wide application of monoclonal antibodies in the field of tumor research,the development of monoclonal antibodies for the treatment of multidrug-resistant bacterial infections has gradually attracted attention.At present,certain progress has been made in laboratory research,and the clinical trials of some products have also achieved good results,but they have not been widely used in clinical practice.This article reviews the types,advantages and related clinical trials of antimicrobial monoclonal antibodies,and looks forward to the future development and challenges.
万方数据
维普
